Table 1.
Expression of VISTA in breast cancer subpopulations with different clinicopathological characteristics.
| Clinicopathological characteristic | Group | Number | VISTA | P-value | |
|---|---|---|---|---|---|
| Pos (n, %) | Neg (n, %) | ||||
| ≥55 | 163 (50.77%) | 76 (46.63%) | 87 (53.37%) | ||
| Age (n = 321) | 0.146 | ||||
| <55 | 158 (49.22%) | 61 (38.61%) | 97 (61.39%) | ||
| Pathological Grade (n = 299) | I-II | 171 (57.19%) | 59 (34.50%) | 112 (65.97%) | |
| 0.001* | |||||
| III | 128 (42.81%) | 69 (53.91%) | 59 (46.097%) | ||
| T1 | 95 (31.46%) | 38 (40.00%) | 57 (60.00%) | ||
| T-category (n = 302) |
T2 | 188 (62.25%) | 80 (42.55%) | 108 (57.45%) | 0.354 |
| T3-T4 | 19 (6.29%) | 11 (57.89%) | 8 (42.11%) | ||
| N0 | 189 (81.81%) | 89 (47.09%) | 100 (52.91%) | ||
| Lymph Node Status (n = 231) | N1 | 51 (22.08%) | 15 (29.41%) | 36 (70.59%) | |
| 0.045* | |||||
| N2 | 48 (20.78%) | 18 (37.50%) | 30(62.508%) | ||
| N3 | 7 (3.03%) | 5 (71.43%) | 2(28.57%) | ||
| Luminal | 94 (48.45%) | 30 (31.91%) | 64(68.09%) | ||
| Genotype (n = 194) | HER 2+ | 7 (3.61%) | 3 (42.86%) | 4(57.14%) | <0.001* |
| Basal-like | 93 (47.94%) | 64 (68.82%) | 29(31.18%) | ||
VISTA, V-domain Ig suppressor of T cell activation; Pos, positive; Neg, negative.
In bold: *p < 0.05, Indicates a statistically significant difference.